Adar1 takes incubated biotech towards $347m Nasdaq listing



 

Biotech hedge fund Adar1 Capital Management is taking a company it founded and incubated towards a Nasdaq listing, marking an unusual expansion from investing in drug developers to building one itself.

AFI subscriber access is required to view this content
AFI provides proprietary intel and business development tools for professionals navigating the global hedge fund market.
AFI Intelligence includes access to Intel, Analysis, Podcasts and Summits.
AFI Intelligence + Data includes everything in AFI Intelligence, plus Research and Data, including AFI’s proprietary rankings, trackers and market research.